跳至主要内容
临床试验/CTRI/2023/08/056921
CTRI/2023/08/056921尚未招募3 期

Potential effects of vamana and virechana karma in negative symptoms of schizophrenia-A randomised open label study - NA

DrAkhila Soman0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Diagnosed patients of Unmada according to Ayurveda and patients of Schizophrenia as per DSM-5-TR
  • Patients with predominant Negative symptoms (Any of the 4 Global scores of
  • Scale for the Assessment of Negative Symptoms- SANS= 3).
  • Mild or lesser level of positive symptoms (Global score of all items of Scale for
  • the Assessment of Positive Symptoms SAPS < 3)
  • Patients who are in the capacity to provide informed consent (as assessed by
  • UBACC- University of California, San Diego Brief Assessment of Capacity to
  • Consent (UBACC) will be recruited. Those who do not have the capacity, caregiver’s consent will be
  • Patients who are on stable medications for atleast 1 month.

排除标准

  • Patients with bipolar affective disorder, substance use disorders (except
  • nicotine and caffeine), major systemic illness, neurological disorders and
  • immune system disorders.
  • Patients with suicidal tendencies.
  • Patients scoring > 7 in Hamilton Depression Rating Scale.
  • Pregnant and lactating mothers.
  • Patients unsuitable for Vamana procedure – heart diseases, severe hepatic,
  • renal or pulmonary dysfunction.
  • Patients who have undergone Vamana or Virechana karma in the last 3

研究者

发起方
DrAkhila Soman

相似试验